Navigation Links
It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
Date:9/11/2007

PARAMUS, N.J., Sept. 11 /PRNewswire-USNewswire/ -- If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk factor for developing cancer of the esophagus, the seventh deadliest cancer in men in the United States.

Barrett's esophagus is marked by cellular changes in the lining of the esophagus, which can progress to low-grade, and then high-grade dysplasia -- a level that is highly pre-malignant. These abnormal cellular changes can lead to a type of cancer called esophageal adenocarcinoma, the fastest rising malignancy in the United States, according to the National Institutes of Health.

The Valley Hospital's Center for Barrett's Esophagus and GERD provides cutting-edge diagnostic, treatment, management, and research services for these related conditions. The Center is one of the most comprehensive on the East Coast and unique to northern New Jersey. The physician team includes board-certified gastroenterologists and thoracic surgeons.

Diagnostic and treatment methods available at the Center include endoscopy, medications to reduce acid, minimally invasive surgical procedures to repair hiatal hernias and to prevent acid reflux, radiofrequency ablation to destroy abnormal cells, endoscopic mucosal resection to remove nodules within Barrett's esophagus, and esophageal cancer surgery.

Robert J. Korst, M.D., Medical Director of The Valley Hospital's Daniel and Gloria Blumenthal Cancer Center, and Director of Thoracic Surgery, says he and physicians at the Center for Barrett's Esophagus and GERD must take a two-prong approach to treating Barrett's esophagus that both destroys the abnormal lining and stops acid reflux.

"Radiofrequency ablation can get rid of the lining, but if the GERD is not controlled, those abnormal cells can grow back and put the patient at risk for cancer once again," he adds.

If Barrett's esophagus progresses into high-grade dysplasia or cancer, the entire esophagus must be removed. Dr. Korst specializes in the treatment and research of esophageal cancer and is highly experienced in using both laparoscopic and traditional surgical methods to remove the esophagus and construct a new one by stretching the stomach.

Barrett's esophagus is most prevalent in middle-aged and elderly Caucasian men but can affect anyone, even those who do not have obvious symptoms of gastroesophageal reflux disease. To learn more about Barrett's esophagus or to schedule an appointment for an evaluation, call The Valley Hospital Center for Barrett's Esophagus and GERD at 201-634-5789


'/>"/>
SOURCE The Valley Hospital
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
8. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
9. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
10. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
11. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. ... for Jardiance (empagliflozin) to reduce the risk of cardiovascular ... and cardiovascular disease. "Cardiovascular disease is ... 2 diabetes mellitus," said Jean-Marc Guettier , M.D., ... Products in FDA,s Center for Drug Evaluation and Research. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder ... Compañía, el INSTI HIV Self Test , a los miembros de la ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... ... surgery can now take advantage of a cosmetic procedure known as Carbon ... that reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, ...
(Date:12/2/2016)... ... , ... Lori G. Cohen and Sara K. Thompson , ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place ... conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than ... Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. ... for area students and operating support to UNCF-member institutions, including Miles College, Oakwood ...
(Date:12/2/2016)... , ... December 02, 2016 , ... The annual time ... Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are ... or prescription drug plan (Part D) need to make changes during this period order ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
Breaking Medicine News(10 mins):